Aligned Genetics, Inc (238120) Fair Value & Analysis
Healthcare · KR · Market cap 40.7B KRW
Fair value as of: Jul 20, 2026
From 14 valuation models · updated 20 days ago
Share price −6.2% over the past month.
Below-average quality, and screening another 29% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2,472 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 2,615 KRW – 6,225 KRW · fair‑value band 1,795 KRW – 2,472 KRW · the 3,095 KRW price screens above the 2,183 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Aligned Genetics, Inc (238120) currently trades at 3,095 KRW, while our model-based Fair Value estimate is 2,183 KRW, implying the stock looks roughly 29.5% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Aligned Genetics, Inc generated revenue of 15.7B KRW at a net margin of 17.6%. Revenue declined 7.2% year over year. It earns a return on equity of 7.6%. Fundamentals as of Jul 20, 2026
Our scenario range runs from 1,795 KRW (bear case) to 2,472 KRW (bull case); at 3,095 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -29%, 238120 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (3,293 KRW) versus Multiples (1,564 KRW). Highest evidence: ROIC Compounder (72).
Notify me when 238120 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc.
Full company description
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aligned Genetics, Inc reported revenue of 16.0B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +8.0%/yr. Reported net income was 2.9B KRW in FY2025, compounding −14.9%/yr from FY2021.
238120 screens 29% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Aligned Genetics, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aligned Genetics, Inc (238120) overvalued or undervalued?
What is the fair value of 238120?
What is the quality score of 238120?
What is the revenue of Aligned Genetics, Inc (238120)?
What is the net profit margin of 238120?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Aligned Genetics, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.